Dr. Tjan-Heijnen on Results of DATA Study in Breast Cancer

Vivianne Tjan-Heijnen, MD, PhD
Published: Thursday, Feb 09, 2017



Vivianne Tjan-Heijnen, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, discusses the results of the phase III DATA study.

Conducted in The Netherlands, this multicenter study compared 3 years versus 6 years of anastrozole after 2 to 3 years of tamoxifen in postmenopausal women with hormone receptor-positive early-stage breast cancer.

Patients with large tumors who were both estrogen-receptor positive and progesterone receptor-positive received a significant benefit from extending treatment.

Tjan-Heijnen believes that questions around relapse with endocrine treatment remain, but adds that new targeted therapies look promising.
 


Vivianne Tjan-Heijnen, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, discusses the results of the phase III DATA study.

Conducted in The Netherlands, this multicenter study compared 3 years versus 6 years of anastrozole after 2 to 3 years of tamoxifen in postmenopausal women with hormone receptor-positive early-stage breast cancer.

Patients with large tumors who were both estrogen-receptor positive and progesterone receptor-positive received a significant benefit from extending treatment.

Tjan-Heijnen believes that questions around relapse with endocrine treatment remain, but adds that new targeted therapies look promising.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x